Tag: Ellipta

Trelegy Ellipta filing accepted by EMA for asthma

by Anna Smith | Feb 28, 2020 | News | 0

As it stands there is no single inhaled triple therapy available for the treatment of asthma in Europe.

Vectura wins patent litigation battle against GSK, awarded $89.7M

by Anna Smith | May 7, 2019 | News | 0

The companies had entered into an agreement in 2010 under which GSK had taken a license to formulation technology covered by a Vectura patent family.

Hikma, Vectura to develop generic rivals to GSK’s Ellipta portfolio

by Selina McKee | Nov 9, 2018 | News | 0

Hikma Pharmaceuticals and Vectura have signed a deal to develop and market generic versions of GlaxoSmithKline’s Ellipta portfolio, utilising the latter’s Open-Inhale-Close dry powder inhaler device.

GSK happy with 3 percent rise in 2017 sales

by Selina McKee | Feb 8, 2018 | News | 0

GlaxoSmithKline has reported a sales hike of 3 percent at constant exchange rates (CER*) for 2017, after growth was recorded across all of its three global businesses.